Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Is there any role for adjuvant radiotherapy for resected multistation N2 atypical carcinoid tumor of the lung?
Related Questions
Is there a role for radiation to the primary mediastinal disease in metastatic thymic neuroendocrine carcinoma with the primary as the only residual disease after systemic therapy?
Would a metal endobronchial stent within the treatment field change your radiation treatment plan for a thoracic malignancy?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
Is there a role for the addition of radiation to preoperative chemoimmunotherapy in NSCLC with limited N2 disease planned for surgery?
Do you still offer adjuvant chemotherapy and chemoradiation for NSCLC after neoadjuvant chemoimmunotherapy?
Would you offer SBRT as an alternative to surgery for an atypical carcinoid lung tumor?
Is moderately hypofractionated RT using 60 Gy/20fx with concurrent chemotherapy appropriate for unresectable stage III NSCLC?
What are your top takeaways in Thoracic Cancers from ASTRO 2024?
Is there a chest wall constraint you typically use for 60 Gy in 15 fraction NSCLC treatment?
Do you use an LAD constraint in the setting of BID thoracic radiation for SCLC?
